The monthly price of the 2.5 mg Zepbound single-dose vial is $399 and the 5 mg dose is $549, which Lilly officials said is in line with the savings program for without insurance.
Zepbound Release
Lilly has released a single-dose vial version of Zepbound (tirzepatide) for self-pay patients. The single-dose is available in 2.5 mg and 5 mg doses.
Usage of Zepbound
Zepbound is used to treat adults who are obese or overweight with related health risks. Tirzepatide is also known as Mounjaro for treating type 2 diabetes.
Mechanism of Action
Zepbound works by activating hormone receptors in the intestine to reduce appetite and food intake.
Pricing
The cost for a four-week supply of Zepbound is $399 for the 2.5 mg dose and $549 for the 5 mg dose, aligning with Lilly’s savings program for non-covered patients.
Sales Performance
Zepbound generated $1.76 billion in sales during the first six months of 2024, being launched to treat obesity and related conditions.
Clinical Success
A clinical study showed that the 5 mg dose helped patients achieve an average of 15% weight loss after 72 weeks, reinforcing its effectiveness as a weight loss tool.
Regulatory Efforts
Lilly is continuing to submit tirzepatide for regulatory approval in treating various conditions, including obstructive sleep apnea.
